SARS-CoV-2 Spike (975-989)
IDRLITGRLQSLQTY is an epitope from the SARS-CoV-2 spike protein (975-989). It is an epitope suitable for anti-viral targeting.
Catalogue number crb1001783 Molecular Weight 1776.0 Sequence (one letter code)
Sequence (three letter code)
Purity >95% Storage -20°C References
Ahmed et al., (2020). Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses, 12(3): 254. DOI: 10.3390/v12030254.
Manufactured in: United Kingdom
The SARS-CoV-2 spike protein is present on the outside of the virus particles and can bind to angiotensin-converting enzyme II (ACE2) present on the host cells. The C-terminal receptor binding domain (RBD) of the spike protein binds to the N-terminal peptidase M2 domain of ACE2. This receptor binding results in the internalisation of the virus-receptor complex and is, therefore the mechanism of entry of SARS-CoV-2 into host cells.
The spike protein residues IDRLITGRLQSLQTY (975-989) from C have been identified as a T-cell epitope with a predicted HLA restriction. Immune targeting of confirmed epitopes may potentially offer protection against SARS-CoV-2 and help the development of vaccines for long-lasting immunity.